Diagnostics: The ‘new black’ of biotech
New Zealand research has found three new tools for diagnosing heart attacks, prostate cancer and infectious diseases.
Scientists are terming diagnostics “the new black” of biotechnology as big pharma search for quicker and more cost-effective methods to diagnose disease.
Diagnostics companies aim to tailor medical treatments, create more precision in disease diagnosis and treatments and reduce costs in
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Fri, 13 Oct 2017
Fri, 13 Oct 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Diagnostics: The ‘new black’ of biotech
70792